The EMPA-REG outcome study demonstrated that the sodium-glucose cotransporter 2 inhibitor (SGLT2i), empagliflozin, significantly lowered death from cardiovascular causes (38%), heart failure hospitalization (35%) and death from any cause (32%) [3]. Here, SLC5A2 is linked to heart failure.